At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 40 enrolled
Drug / intervention
Guazuma Ulmifolia plus Tecoma Stans +1 moredrug
Likely dose
Guazuma Ulmifolia plus Tecoma Stans 313.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Oral Administration of a Herbarium Mixture (Guazuma Ulmifolia and Tecoma Stans) on Metabolic Profile in Type 2 Diabetic Patients
Centro Universitario de Ciencias de la Salud, Mexico·interventional·Posted Oct 18, 2017·Updated Oct 18, 2017
In Brief
A Phase 3 clinical trial evaluating Guazuma Ulmifolia plus Tecoma Stans and Calcinaned magnesia for Type 2 Diabetes Mellitus. Completed, enrolled 40 participants.
Detailed Summary
To evaluate the effect of oral administration of herbarium mixture Guazuma ulmifolia (GU) and Tecoma stans (TS) on metabolic profile in type 2 diabetic patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
Primary CompletionDec 2010
Study CompletionMay 2011
First PostedOct 2017
TodayJul 2026
First PostedOct 18, 2017
Enrollment StartJan 10, 2010
Primary CompletionDec 31, 2010
Study CompletionMay 31, 2011
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 8.7 years ago
Interventions
Guazuma Ulmifolia plus Tecoma Stansdrug
Guazuma ulmifolia (313.6 mg) -Tecoma stans (86.4 mg) = 400 mg per capsule
Calcinaned magnesiadrug
Calcined magnesia 400 mg per capsule